Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Decreases By 14.1%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 16,400 shares, a decrease of 14.1% from the December 15th total of 19,100 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 25,600 shares, the days-to-cover ratio is presently 0.6 days.

Lisata Therapeutics Stock Performance

Shares of Lisata Therapeutics stock opened at $3.72 on Friday. The company’s 50-day moving average price is $3.00 and its two-hundred day moving average price is $3.06. Lisata Therapeutics has a 52 week low of $2.19 and a 52 week high of $4.20. The stock has a market cap of $31.21 million, a PE ratio of -1.48 and a beta of 1.14.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.16. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. On average, equities analysts predict that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.